Apitegromab is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase III program in Spinal Muscular Atrophy (SMA). According to Globaldata, it is involved in 7 clinical trials, of which 2 were completed, 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Apitegromab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Apitegromab is expected to reach an annual total of $433 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Apitegromab Overview

Apitegromab (SRK-015) is under development for the treatment of type 2 and type 3 spinal muscular atrophy (SMA) and obesity. It is administered through Intravenous route. The drug candidate is a niche modulator inhibiting activation of the latent myostatin precursor. It was under development for the treatment of Becker muscular dystrophy and other muscle wasting disorders (additional myostatin related disorders).

Scholar Rock Holding Overview

Scholar Rock Holding (Scholar Rock) is a clinical-stage biopharmaceutical company that develops novel medicines for the treatment of severe diseases in which signaling by protein growth factors plays a fundamental role. The company’s pipeline products comprise SRK-015, an inhibitor for the treatment of spinal muscular atrophy (SMA). It also develops inhibitors of latent TGFß1 for the treatment of immune oncology and fibrosis. Scholar Rock serves in the therapeutic areas of neuromuscular disorders, fibrosis, cancer and also anemia. The company has collaborated with Gilead Sciences Inc to discover and develop specific inhibitors. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Apitegromab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.